Redeye comments on Scandion’s Q1 2021 report, which came without any surprises. CORIST phase II part 1 readout is just around the corner, as is preclinical data from Scandion’s immuno-oncology collaboration with Alligator Biosciences. Scandion is in a healthy financial position, with cash holdings to fund operations into 2023.